NanoHarmonics
NanoHarmonics Inc. is dedicated to developing advanced diagnostic, data management, and drug delivery technologies to revolutionize healthcare. Their mission is to bring the next generation of converging technologies in diagnostics, information science, and drug delivery systems to save lives. They focus on rapid, portable, and quantitative bio-diagnostics using Quantum Dot technology, complemented by secure data platforms and innovative drug delivery systems. The company collaborates globally with universities, pharmaceutical companies, and non-profit organizations to create predictive models and improve disease management and personal health monitoring.
Industries
Nr. of Employees
small (1-50)
Products
Rapid quantitative quantum dot diagnostic (finger‑prick)
A portable diagnostic test and reader that uses quantum dot fluorescence and a finger‑prick blood sample to provide rapid, quantitative biomarker measurements for point-of-care and at‑home use.
Quantitative SARS‑CoV‑2 neutralizing antibody test (blood)
A quantitative assay and device intended to measure neutralizing antibody levels against SARS‑CoV‑2 (N‑protein), producing a numerical value indicative of immunity level.
SARS‑CoV‑2 antigen nasal test (quantitative)
A nasal‑specimen antigen test and device designed for ease of use similar to standard antigen swabs but providing a quantitative output and high reported accuracy in preliminary validations.
Rapid quantitative sepsis test (prototype)
A rapid quantitative diagnostic under development intended to detect biomarkers associated with sepsis to reduce time-to-diagnosis and improve clinical outcomes.
Persistent antiviral/antibacterial surface sanitizer (commercialized rights)
A US‑patented persistent sanitizer claimed to kill viruses and bacteria for extended periods; being commercialized through a subsidiary focused on applied sciences.
Anti-mosquito paint (long‑lasting)
A US‑patented anti‑mosquito paint intended to repel and kill mosquitoes for a multi-year period; intended for commercialization in equatorial regions as part of vector-control initiatives.
Rapid quantitative quantum dot diagnostic (finger‑prick)
A portable diagnostic test and reader that uses quantum dot fluorescence and a finger‑prick blood sample to provide rapid, quantitative biomarker measurements for point-of-care and at‑home use.
Quantitative SARS‑CoV‑2 neutralizing antibody test (blood)
A quantitative assay and device intended to measure neutralizing antibody levels against SARS‑CoV‑2 (N‑protein), producing a numerical value indicative of immunity level.
SARS‑CoV‑2 antigen nasal test (quantitative)
A nasal‑specimen antigen test and device designed for ease of use similar to standard antigen swabs but providing a quantitative output and high reported accuracy in preliminary validations.
Rapid quantitative sepsis test (prototype)
A rapid quantitative diagnostic under development intended to detect biomarkers associated with sepsis to reduce time-to-diagnosis and improve clinical outcomes.
Persistent antiviral/antibacterial surface sanitizer (commercialized rights)
A US‑patented persistent sanitizer claimed to kill viruses and bacteria for extended periods; being commercialized through a subsidiary focused on applied sciences.
Anti-mosquito paint (long‑lasting)
A US‑patented anti‑mosquito paint intended to repel and kill mosquitoes for a multi-year period; intended for commercialization in equatorial regions as part of vector-control initiatives.
Services
Design and development of an encrypted data platform with blockchain integration for anonymized aggregation, analytics and population surveillance of biomarker results.
Operational design and execution of population-level surveillance studies, including logistics, field testing, and integration of diagnostics results with secure data platforms.
Partnership services for reformulation and development of drug delivery systems, biomarker-guided clinical testing, and coordination of clinical trials and regulatory processes.
Support for establishing toll manufacturing, regulatory submissions, and distribution channel relationships across Southeast Asia.
Engineering services for microfluidic integration, miniaturized assay formats and portable reader development for point-of-care deployment.
Design and development of an encrypted data platform with blockchain integration for anonymized aggregation, analytics and population surveillance of biomarker results.
Operational design and execution of population-level surveillance studies, including logistics, field testing, and integration of diagnostics results with secure data platforms.
Partnership services for reformulation and development of drug delivery systems, biomarker-guided clinical testing, and coordination of clinical trials and regulatory processes.
Support for establishing toll manufacturing, regulatory submissions, and distribution channel relationships across Southeast Asia.
Engineering services for microfluidic integration, miniaturized assay formats and portable reader development for point-of-care deployment.
Expertise Areas
- Quantum dot diagnostics
- Biomarker assay development
- Point-of-care & direct-to-consumer diagnostic development
- Clinical trial design and validation for diagnostics
Key Technologies
- Quantum dot fluorescence assays
- Nanoparticle bio-conjugation
- Multiplexed fluorescence detection
- Blockchain for data integrity
News & Updates
NanoHarmonics Asia, Inc., headquartered in Manila, Philippines, is building supply chain, distribution, R&D, and strategic partnerships in Southeast Asia, including clinical trial collaborations and agreements with major pharmaceutical companies.
NanoHarmonics Asia, Inc., headquartered in Manila, Philippines, is building supply chain, distribution, R&D, and strategic partnerships in Southeast Asia, including clinical trial collaborations and agreements with major pharmaceutical companies.